Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Trinity Biotech (TRIB) Operating Leases (2019 - 2025)

Historic Operating Leases for Trinity Biotech (TRIB) over the last 7 years, with Q2 2025 value amounting to $10.6 million.

  • Trinity Biotech's Operating Leases rose 348.07% to $10.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was $10.6 million, marking a year-over-year increase of 348.07%. This contributed to the annual value of $10.5 million for FY2024, which is 363.32% down from last year.
  • Latest data reveals that Trinity Biotech reported Operating Leases of $10.6 million as of Q2 2025, which was up 348.07% from $10.5 million recorded in Q4 2024.
  • In the past 5 years, Trinity Biotech's Operating Leases registered a high of $13.9 million during Q4 2021, and its lowest value of $9.7 million during Q3 2024.
  • Over the past 5 years, Trinity Biotech's median Operating Leases value was $10.9 million (recorded in 2023), while the average stood at $11.3 million.
  • Its Operating Leases has fluctuated over the past 5 years, first crashed by 1641.55% in 2021, then skyrocketed by 348.07% in 2025.
  • Trinity Biotech's Operating Leases (Quarter) stood at $13.9 million in 2021, then fell by 11.53% to $12.3 million in 2022, then decreased by 11.37% to $10.9 million in 2023, then decreased by 3.63% to $10.5 million in 2024, then rose by 0.73% to $10.6 million in 2025.
  • Its last three reported values are $10.6 million in Q2 2025, $10.5 million for Q4 2024, and $9.7 million during Q3 2024.